Company intelligence / Profile preview

SpinaFX Medical

Toronto, Ontario, Canadaspinafx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Preliminary clinical data suggest that Triojection®, an outpatient minimally invasive image-guided ozone/oxygen injection therapy for contained lumbar herniated discs, may reduce disc volume and nerve pressure. The therapy has not yet received regulatory approval in the US, Canada, EU or elsewhere. Further clinical validation and regulatory review are ongoing.

Therapeutic areas: RheumatologyNeurology
Modalities: DeviceNon-pharmacological therapy (minimally invasive image-guided oxygen/ozone injection)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Triojection

Pre-clinical

Indications: Lumbar disc herniation, Back pain, Radiculopathy

Partnerships

StarFish Medical (contract manufacturing support)

Beyond the preview

Go deeper on SpinaFX Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpinaFX Medical.

Explore the full profile